Position in GSK
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$51,357,970
-$18,152,565 QoQ
Shares Held
979,740
-22.2% QoQ
Ownership
0.049%
of shares outstanding
% of Portfolio
3.38%
of 13F equity value
Holder Rank
#43
of 1,033 holders
Holding Since
Dec 2022
15 quarters on record
Voting authority
Sole 95%
Shared 0%
None 5%
Common Shares in GSK Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Callodine Capital Management, LP holds $51,357,970 across 1 Drug Manufacturers - General name. GSK ranks #1 (100.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | GSK |
GSK plc
This page
|
979,740 | $51,357,970 |
All Filings in GSK
Export CSV
15 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $51,357,970 | 979,740 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $69,510,535 | 1,259,477 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $49,252,196 | 1,004,327 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $30,300,521 | 702,051 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $22,983,129 | 598,519 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $22,081,800 | 570,000 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $23,674,000 | 700,000 | Shares | Sole | 2025-02-13 | |
| 2024-09-30 | $24,732,400 | 605,000 | Shares | Sole | 2024-11-13 | |
| 2024-06-30 | $20,790,000 | 540,000 | Shares | Sole | 2024-08-13 | |
| 2024-03-31 | $17,148,000 | 400,000 | Shares | Sole | 2024-05-14 | |
| 2023-12-31 | $16,677,000 | 450,000 | Shares | Sole | 2024-02-14 | |
| 2023-09-30 | $17,218,750 | 475,000 | Shares | Sole | 2023-11-13 | |
| 2023-06-30 | $16,038,000 | 450,000 | Shares | Sole | 2023-08-14 | |
| 2023-03-31 | $16,011,000 | 450,000 | Shares | Sole | 2023-05-12 | |
| 2022-12-31 | $7,379,400 | 210,000 | Shares | Sole | 2023-02-13 | |
| No filing history on record for this holder in this stock. | ||||||